Advertisement

Neurotherapeutics

, Volume 16, Issue 3, pp 912–919 | Cite as

ASENT 2019 Abstracts

Abstracts
  • 110 Downloads

Active Immunotherapeutic Vaccine Platform Targeting Endogenous Proteins for the Treatment of Neurodegenerative Diseases

Sharon Tamir; Hui Jing Yu, PhD; JC Dodart, PhD; and Chang Yi Wang, PhD; all of United Neuroscience

United Neuroscience (UNS) is pioneering a new class of active immunotherapeutics to promote brain health, focusing on delivering safe, effective and accessible medicines to treat and ultimately prevent Alzheimer’s (AD), Parkinson’s disease (PD) and other neurological disorders. Leveraging a proven vaccine platform that has commercialized one of the only licensed active immunotherapies against an endogenous protein in the world and has scaled up manufacture to over 500 million doses annually for other animal indications.

Success for a vaccine approach aimed at endogenous targets relies on the ability to break immune tolerance and generate a humoral antibody response against the desired epitopes, while also avoiding T-cell-mediated autoimmune reactions. UNS has evolved a...

Notes

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2019

Personalised recommendations